Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Current data on neurologic sequelae caused by neuroleptics]

M O Krebs1

  • 1Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Hôpital Sainte-Anne, Paris.

L'Encephale
|June 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Theory of mind variability in schizophrenia: A neurodevelopmental perspective through neurological soft signs and premorbid adjustment.

Schizophrenia research. Cognition·2025
Same author

Theory of mind in schizophrenia through a clinical liability approach: a sib-pair study.

Frontiers in psychology·2024
Same author

Association and epistatic analysis of white matter related genes across the continuum schizophrenia and autism spectrum disorders: The joint effect of NRG1-ErbB genes.

The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry·2021
Same author

Paris MEM: a study protocol for an effectiveness and efficiency trial on the treatment of traumatic stress in France after the 2015-16 terrorist attacks.

BMC psychiatry·2019
Same author

Influence of DAOA and RGS4 genes on the risk for psychotic disorders and their associated executive dysfunctions: A family-based study.

European psychiatry : the journal of the Association of European Psychiatrists·2016
Same author

Confidence and psychosis: a neuro-computational account of contingency learning disruption by NMDA blockade.

Molecular psychiatry·2015
Same journal

Measuring antidepressant side effects in military personnel - Clinical validation of the French version of the UKU-SERS-Pat Scale: A comparative study of patient and clinician ratings.

L'Encephale·2026
Same journal

[Empowerment in addictology].

L'Encephale·2026
Same journal

Evaluation of the links between smoking and conspiracy mentality.

L'Encephale·2026
Same journal

Use of a relevance assessment tool in therapeutic residential care: A real world study.

L'Encephale·2026
Same journal

Prevalence and characteristics of domestic violence in a sample of adult psychiatric outpatients: A cross-sectional study.

L'Encephale·2026
Same journal

From representations to practice: how professionals describe supporting parents with psychiatric or somatic illness or disability.

L'Encephale·2026
See all related articles

Atypical neuroleptics offer antipsychotic efficacy with fewer neurological side effects, potentially by targeting the mesocorticolimbic dopaminergic system. Clozapine

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Context:

  • Neuroleptic drugs historically defined by neurological effects.
  • Atypical neuroleptics demonstrate efficacy with minimal neurological side-effects.
  • Mechanisms of
  • atypicality
  • remain incompletely understood.

Purpose:

  • To explore the neurobiological mechanisms underlying atypical neuroleptic action.
  • To investigate the potential benefits of atypical neuroleptics in patients with tardive dyskinesia.
  • To assess the specific role of clozapine in managing tardive dyskinesia.

Summary:

  • Atypical neuroleptics may achieve antipsychotic effects through preferential action on the mesocorticolimbic dopaminergic system.

Related Experiment Videos

  • This targeted action could be advantageous for patients with severe tardive dyskinesia.
  • Clozapine treatment cessation did not exacerbate pre-existing dyskinesia, suggesting a favorable long-term prognosis for dyskinetic patients.

    • Impact:

    • Findings suggest atypical neuroleptics, particularly clozapine, may offer a safer treatment option for patients with both psychosis and movement disorders.
    • Further research is needed to determine if this benefit extends to other atypical neuroleptics.
    • This could lead to revised treatment guidelines for managing complex psychiatric conditions.